Palbociclib (PD-0332991) HCl

For research use only. Not for use in humans.

Licensed by Pfizer 製品コードS1116

分子量(MW)：483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ

価格(税別)

在庫

5mg	JPY 20200	あり
10mg	JPY 30200	あり
50mg	JPY 96600	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(155)

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明

特性

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

ターゲット

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	NHjNcplMcW6jc3WgRZN{[Xl?		NUDxc3FMOjRiaB?=		NIKwU5FKdmirYnn0bY9vKG:oIFPET\|Qh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzKM7:TR?=	MViyOFY1OTFyMx?=
COLO205	NVvXPXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlHCO\|IhcA>?		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=>	NHrH[mczPDZ2MUGwNy=>
U937	NGLoW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVL5PIZ5PzJiaB?=		MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN	M2q3V\|I1PjRzMUCz
MOLM13	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\YO\|IhcA>?		M3KwNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR\|IFnUSEBufXSjboSgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0>	MUKyOFY1OTFyMx?=
MOLM13	NV3hWpVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV23NkBp		MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	MlPXNlQ3PDFzMEO=
MDA-MB-435	NYLobm9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPHWYl4OjRiaB?=		MX;JR\|UxRTBwMU[g{txO	MnfiNVU5ODF6M{G=
K562	NEf4eVFEgXSxdH;4bYMhSXO\|YYm=		Mnn6PVYhcA>?	NWK5eXNkTE2VTx?=	NU\CbItCUUN3ME2yJO69VQ>?	MVyyOFQyPzV4Nh?=
DU145	MlTWR5l1d3SxeHnjJGF{e2G7		MknFPVYhcA>?	M1rT[mROW09?	M3PqcmlEPTB;Nz61JO69VQ>?	MUKyOFQyPzV4Nh?=
MDA-MB-231	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjyNUDPxE1?	M2DTT\|I1KGh?	M2XNWmROW09?	MVLD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS\|EheGijc3W=	MnLpNlQ1OTd3Nk[=
MCF7	NIPve4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnQNUDPxE1?	MX2yOEBp	MkD4SG1UVw>?	NHrOV\|NE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	M1vCdlI1PDF5NU[2
MCF7	MYfLbY5ie2ViQYPzZZk>	MoD1OUDPxE1?	MYKyOEBp	Mlj4SG1UVw>?	MU\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET\|Qw[3mlbHnuSFEh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy	Ml\SNlQ1OTd3Nk[=
MDA-MB-231	NV3yTXNPU2mwYYPlJGF{e2G7	M{juUFUh\|ryP	NV3VZndUOjRiaB?=	MkTOSG1UVw>?	NGjtVIZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG\|dH;tZUBxcG:\|cHjvdplt[XSrb36gZZQhW2W{N{iw	M4jwZ\|I1PDF5NU[2
MDA-MB-231	Mk\uSpVv[3Srb36gRZN{[Xl?	NGC5UHMyNTFyIN88US=>	NEPJSFMzPCCq	NYmyRZVPTE2VTx?=	MkCy[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen	M1jTcVI1PDF5NU[2
MCF7	NUTZV3duTnWwY4Tpc44hSXO\|YYm=	NV;BbWN3OS1zMDFOwG0>	MWeyOEBp	M1HKb2ROW09?	M171XYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	Mo\QNlQ1OTd3Nk[=
MDA-MB-231	NHTlXolHfW6ldHnvckBCe3OjeR?=	M1:1SFAvPS1zIN88US=>	NV\HdWh4PDhiaB?=	NVqyUJZSTE2VTx?=	NX\6ZYdDcGG\|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?	M{K1ZVI1PDF5NU[2
MCF7	MWHGeY5kfGmxbjDBd5NigQ>?	MmL0NE42NTFizszN	MUm0PEBp	NF7HempFVVOR	MXHoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	NYizRnRlOjR2MUe1OlY>
697	M{jCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXue2I3UUN3ME2xOFgvOzhibl2=	NIjVV3JUSU6JRWK=
P12-ICHIKAWA	NGjGWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPCTWM2OD17Nj6wOEBvVQ>?	NUHDbnJPW0GQR1XS
NB69	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrpTWM2OD1zNkGuPEBvVQ>?	M2nQNXNCVkeHUh?=
EoL-1	M1jSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTF6Nz6yOkBvVQ>?	M4TNSnNCVkeHUh?=
BHT-101	M1TGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHsSHh6UUN3ME2xPVgvOjVibl2=	M3;aOnNCVkeHUh?=
SK-NEP-1	NYDBXpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYqwV5huUUN3ME2yNlAvODJibl2=	NIPEbFNUSU6JRWK=
MHH-NB-11	NXvRSm9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHnTWM2OD1{MkCuNVkhdk1?	MXnTRW5ITVJ?
AsPC-1	NInmUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LpOWlEPTB;MkWyMlU{KG6P	M1:2VnNCVkeHUh?=
ES1	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzaZlJFUUN3ME2yOVYvOjVibl2=	Ml;OV2FPT0WU
LAMA-84	Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTJ3OD6xPUBvVQ>?	M2fsV3NCVkeHUh?=
MOLT-16	NUe3TlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJ3OD60PUBvVQ>?	MVnTRW5ITVJ?
ES7	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJ5Mz6wPUBvVQ>?	MUnTRW5ITVJ?
KY821	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvR[FVjUUN3ME2zNVQvOSCwTR?=	NXzjNYFKW0GQR1XS
RT-112	NXPNc3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NICycHlKSzVyPUOyNU4xPSCwTR?=	MVXTRW5ITVJ?
HL-60	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfVTWM2OD1\|NECuOlYhdk1?	MkLoV2FPT0WU
MOLT-4	NIj6WXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;pcmlEPTB;M{S1MlE{KG6P	NX3r[HBPW0GQR1XS
KARPAS-45	NXLsXlI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGixNGJKSzVyPUO3Ok4yPiCwTR?=	MUnTRW5ITVJ?
SK-N-AS	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTN6Nz64N{BvVQ>?	NXv3XVljW0GQR1XS
CTB-1	NH\pUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjXTnZKSzVyPUSwOU4xOiCwTR?=	NUnjc5lTW0GQR1XS
NKM-1	M1niO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PQUmlEPTB;NEGxMlg6KG6P	M3X6eXNCVkeHUh?=
HTC-C3	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTR\|Mj65OUBvVQ>?	NF3JSpdUSU6JRWK=
BE-13	M33wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnXVGJrUUN3ME20OFQvOjdibl2=	MlnVV2FPT0WU
KOSC-2	NWmzVIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH20XY5KSzVyPUS2Ok46KG6P	MWDTRW5ITVJ?
NB14	MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkO4TWM2OD12OEOuOVghdk1?	M2XBUHNCVkeHUh?=
CAL-27	M1PSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\EUHlWUUN3ME20PVQvPTlibl2=	MXTTRW5ITVJ?
H9	NFLqb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\I[JRVUUN3ME20PVUvPDNibl2=	M1vufHNCVkeHUh?=
RS4-11	M1HjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTVyND63N{BvVQ>?	M{m3bXNCVkeHUh?=
PA-1	NGfuSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF35boxKSzVyPUWwPU45PiCwTR?=	MVHTRW5ITVJ?
MV-4-11	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3H3e2lEPTB;NUGzMlg2KG6P	MnT4V2FPT0WU
OS-RC-2	NVmyRmpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;NTWM2OD13MkGuOlIhdk1?	M2PsUXNCVkeHUh?=
RPMI-8226	M37acWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\JVFBKSzVyPUWyOk45PiCwTR?=	NHLZNYVUSU6JRWK=
HGC-27	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTV4ND65PUBvVQ>?	MX7TRW5ITVJ?
CHP-212	NVjkZVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K2bWlEPTB;NUmzMlU6KG6P	MXHTRW5ITVJ?
NB10	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXOZ49KSzVyPUW5PU4yQCCwTR?=	MXrTRW5ITVJ?
HH	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HMemlEPTB;NUm5MlQ{KG6P	MYHTRW5ITVJ?
EW-16	NGPhNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDqOGRKSzVyPU[wN{42OiCwTR?=	NIrWS2FUSU6JRWK=
ES8	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXy4T5ZiUUN3ME22NFUvOjFibl2=	NXHMcm1nW0GQR1XS
HAL-01	NGHNcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTiTWM2OD14MEWuOlchdk1?	MXzTRW5ITVJ?
A204	M3ntcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrHd4dKSzVyPU[zN{46OSCwTR?=	NF\0SlZUSU6JRWK=
MHH-PREB-1	Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHESXBKSzVyPU[zOk46QSCwTR?=	M13UU3NCVkeHUh?=
EM-2	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTZ3MD62OEBvVQ>?	NVnrNoRyW0GQR1XS
BV-173	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHF[\|ZKSzVyPU[1Nk41QCCwTR?=	NUD1d2VHW0GQR1XS
ONS-76	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmThTWM2OD14N{euPFIhdk1?	MV3TRW5ITVJ?
KM-H2	NELYb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzCflVKSzVyPU[5OU42PCCwTR?=	MlLmV2FPT0WU
D-263MG	NVHkdWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4i3OGlEPTB;N{G3MlEzKG6P	MljMV2FPT0WU
ES3	NY\L[XJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTd{OD65N{BvVQ>?	NWjmelZ6W0GQR1XS
VA-ES-BJ	NGXLO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTd\|Mj6yO{BvVQ>?	M{niWHNCVkeHUh?=
NBsusSR	NF65b3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ryOGlEPTB;N{SyMlk6KG6P	MVTTRW5ITVJ?
NCI-H520	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XJfmlEPTB;N{S2MlUzKG6P	MWXTRW5ITVJ?
ES5	NH21TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jUSmlEPTB;N{WyMlghdk1?	M2rsZXNCVkeHUh?=
T-24	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Dy[GlEPTB;N{e4MlcyKG6P	MXfTRW5ITVJ?
SW962	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnmxTWM2OD16MEiuOlMhdk1?	NVjJNXdRW0GQR1XS
EW-3	NEmyVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XKbGlEPTB;OEC4Mlc3KG6P	Ml\FV2FPT0WU
RXF393	NEnuNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRThzMj63PUBvVQ>?	Ml3nV2FPT0WU
U251	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3m0U2lEPTB;OEGzMlg5KG6P	M4rjdHNCVkeHUh?=
CAMA-1	M2[wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PIUWlEPTB;OEOzMlk1KG6P	NUTF[pZXW0GQR1XS
JVM-3	M1\3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXhUJZLUUN3ME24OVEvPzhibl2=	MnrlV2FPT0WU
COLO-800	NFPJPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mki4TWM2OD16OUeuO\|ghdk1?	MkPrV2FPT0WU
OVCAR-5	M4HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{D6N2lEPTB;OUCwMlEhdk1?	NIDpfYFUSU6JRWK=
LB1047-RCC	NFfqVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTl{Nz61OkBvVQ>?	NYnaV3VQW0GQR1XS
SW954	M2CwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nnSmlEPTB;OUK5MlQyKG6P	MUHTRW5ITVJ?
J-RT3-T3-5	M2HNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\y[mFKSzVyPUmzOk4xPiCwTR?=	M1nNR3NCVkeHUh?=
Mewo	NH[zTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLtTGNKSzVyPUmzOk43KG6P	MoDRV2FPT0WU
NCI-H1770	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7yO2tjUUN3ME25OFAvPTVibl2=	MnXjV2FPT0WU
HO-1-N-1	M{LXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm4TWM2OD17NkKuPFEhdk1?	NVTsc\|RMW0GQR1XS
HSC-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17IbGlEPTB;OU[2MlQ5KG6P	NILQZ21USU6JRWK=
TYK-nu	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHufWVKSzVyPUm5PE4zPSCwTR?=	MlHUV2FPT0WU
KYSE-150	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknvTWM2OD1zLkCwNFc3KM7:TR?=	NEjsUYdUSU6JRWK=
SN12C	Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HPeWlEPTB;MT6wNFg4PSEQvF2=	NEnq[ldUSU6JRWK=
MOLT-13	NHTYSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7NTWM2OD1zLkCxOFIyKM7:TR?=	NXz6SpMyW0GQR1XS
TE-11	NWO2eYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFwMES4NVIh\|ryP	M2LRWXNCVkeHUh?=
DB	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHT0XGlKSzVyPUGuNFczPzNizszN	MknNV2FPT0WU
CAL-39	M4nkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXqfnNwUUN3ME2xMlA4PTJ{IN88US=>	MVHTRW5ITVJ?
A3-KAW	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHTT3dGUUN3ME2xMlA5PDB6IN88US=>	MVTTRW5ITVJ?
CHP-134	NWLDT4YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFwMUG4NFch\|ryP	M1zzTnNCVkeHUh?=
TGW	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XGXGlEPTB;MT6xNlM6PSEQvF2=	NHe2emRUSU6JRWK=
QIMR-WIL	NX\KR4ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHQTWM2OD1zLkGzNVM1KM7:TR?=	MXvTRW5ITVJ?
NCI-SNU-1	NVyzWVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jDdmlEPTB;MT6xOlM2PCEQvF2=	NH3SN3hUSU6JRWK=
CGTH-W-1	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnDNFVKSzVyPUGuNVcyQDZizszN	NVraW2VDW0GQR1XS
MHH-ES-1	NVLPdHZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwMUe5PFYh\|ryP	NX65d5NlW0GQR1XS
LB2241-RCC	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrYVm0{UUN3ME2xMlE5PjJizszN	NVO0NXBqW0GQR1XS
ML-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4G4XmlEPTB;MT6yNFc{PCEQvF2=	M1HBS3NCVkeHUh?=
COR-L23	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vWeGlEPTB;MT6yNlk{OyEQvF2=	NXrE[XRxW0GQR1XS
BFTC-905	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrXcJpKSzVyPUGuNlQzPjdizszN	MoH4V2FPT0WU
Hs-578-T	M{fGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzsTWM2OD1zLkK1PFE4KM7:TR?=	NInJOIdUSU6JRWK=
KG-1	M4jPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXITWM2OD1zLkK2Olg3KM7:TR?=	M1PNbHNCVkeHUh?=
HEL	NVna[YpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH:5coJKSzVyPUGuNlk{OzhizszN	MlXwV2FPT0WU
A549	M3jXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrFXJRKSzVyPUGuNlk{QTlizszN	MXHTRW5ITVJ?
COLO-741	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFwM{KwPFkh\|ryP	NX\3OGdZW0GQR1XS
PC-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonFTWM2OD1zLkO1NlIyKM7:TR?=	MnjvV2FPT0WU
HOS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2THV2lEPTB;MT6zOVI6PiEQvF2=	NUWydGk2W0GQR1XS
HT-1080	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFwM{e1NVkh\|ryP	MX3TRW5ITVJ?
TE-8	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PhU2lEPTB;MT60NVc4PCEQvF2=	M4nk[3NCVkeHUh?=
BHY	NVrieJQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfnVVB3UUN3ME2xMlQ3QTJ\|IN88US=>	MkTCV2FPT0WU
BB65-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPWb2pKSzVyPUGuOVA2OjhizszN	MmTwV2FPT0WU
HN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjhU\|dDUUN3ME2xMlU1ODdzIN88US=>	M{C0THNCVkeHUh?=
NCI-H441	M3HXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\ZTWM2OD1zLkW0PVA4KM7:TR?=	M3TpOHNCVkeHUh?=
RPMI-8866	NWnDZndkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFwNUi1NFch\|ryP	Mm\QV2FPT0WU
CAL-62	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LZdGlEPTB;MT62NFg3OiEQvF2=	NFrqdo5USU6JRWK=
MG-63	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXe3U4dnUUN3ME2xMlYyQDF\|IN88US=>	MXHTRW5ITVJ?
SK-LU-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELTbHBKSzVyPUGuOlIyPTJizszN	MlvaV2FPT0WU
BCPAP	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X1XmlEPTB;MT62OlQ2PyEQvF2=	M1vZc3NCVkeHUh?=
22RV1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTFwNke4OFMh\|ryP	MXnTRW5ITVJ?
T47D	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\nRWlEPTB;MT62PFA3OSEQvF2=	M3i3UHNCVkeHUh?=
MSTO-211H	NYnvcFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnZTWM2OD1zLk[5OlA{KM7:TR?=	MXvTRW5ITVJ?
DEL	M4TJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjBTWM2OD1zLkewNlc{KM7:TR?=	MVzTRW5ITVJ?
H4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\FVoVKSzVyPUGuO\|MzOTJizszN	M3HUU3NCVkeHUh?=
CAL-51	NVXxcm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;ISmlEPTB;MT63OFg2PSEQvF2=	M3nPTHNCVkeHUh?=
ABC-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPaTWM2OD1zLke4OVgzKM7:TR?=	NHq3UYRUSU6JRWK=
MZ2-MEL	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\aVWlEPTB;MT63PVU1OiEQvF2=	MVPTRW5ITVJ?
YKG-1	NVH1cZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkntTWM2OD1zLkixNFYyKM7:TR?=	MV;TRW5ITVJ?
KM12	M3zhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XnSmlEPTB;MT64NVYxOiEQvF2=	NVHETW5uW0GQR1XS
L-363	NEHJdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjRbm9kUUN3ME2xMlg4PDF{IN88US=>	NHzaNINUSU6JRWK=
KU812	NXLITJB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDlTWM2OD1zLki5NlgzKM7:TR?=	M2jkNHNCVkeHUh?=
LOXIMVI	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnTeJVKSzVyPUGuPVEzOjhizszN	NIHnOo1USU6JRWK=
G-401	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;XOVZKSzVyPUGuPVI1OjhizszN	MoDTV2FPT0WU
SW780	NYTkT3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWe0W3oyUUN3ME2xMlk3OjR4IN88US=>	MnnZV2FPT0WU
SW872	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DLPGlEPTB;MT65PFM{KM7:TR?=	NHrq[pRUSU6JRWK=
NB7	NY\IUnlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFwOUmzNlMh\|ryP	NYC3TWg6W0GQR1XS
T98G	MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvCZmx[UUN3ME2yMlAxPjZ4IN88US=>	M3;HU3NCVkeHUh?=
SW1710	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrGXlFOUUN3ME2yMlA3QTR3IN88US=>	NEPoZW5USU6JRWK=
NCI-H1573	NV;2d4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJwMEeyPVgh\|ryP	NHvl[\|dUSU6JRWK=
KE-37	M1nlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLEO4xKSzVyPUKuNFg6PTFizszN	MXrTRW5ITVJ?
786-0	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJwMUW0N\|kh\|ryP	M1yyVXNCVkeHUh?=
SAS	M2PYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\sTWM2OD1{LkKwN\|c1KM7:TR?=	NX;GPWxKW0GQR1XS
CAL-54	M4\WSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DIW2lEPTB;Mj6yNFQyOyEQvF2=	NXTvXpBXW0GQR1XS
SF268	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\NcWlEPTB;Mj6yN\|EzOiEQvF2=	M4TYSnNCVkeHUh?=
SW620	NGnCeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\lVVZ[UUN3ME2yMlI3OTZ7IN88US=>	MXzTRW5ITVJ?
MN-60	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTJwM{GwOkDPxE1?	MkLKV2FPT0WU
EFO-27	NX;pOYM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TSWWlEPTB;Mj6zNlA2QCEQvF2=	M{fXbXNCVkeHUh?=
NCI-H747	NFW2OIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJwM{KxPVkh\|ryP	M1\qTHNCVkeHUh?=
HCC2218	MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnG2TWM2OD1{LkO1N\|c1KM7:TR?=	NWrSOIo{W0GQR1XS
MIA-PaCa-2	NHu2S2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJwM{[0N\|ch\|ryP	MYDTRW5ITVJ?
SJSA-1	M4XvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfKWYpIUUN3ME2yMlM4Pzl4IN88US=>	NIrJOJNUSU6JRWK=
RKO	NHf0foNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[1TlRKSzVyPUKuN\|g1QTZizszN	Ml7jV2FPT0WU
NB6	NGXuNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJwNECzO\|Qh\|ryP	MYHTRW5ITVJ?
ES4	M13Hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLXO2lKSzVyPUKuOFU1OjJizszN	NHvQcG9USU6JRWK=
EGI-1	NFjPUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnRc4dbUUN3ME2yMlQ3QDh\|IN88US=>	NU\Fb3c1W0GQR1XS
CTV-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJwNUK3O\|Mh\|ryP	MWTTRW5ITVJ?
NCI-H1355	NUfGe5l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXhSYdKSzVyPUKuOVU6PTFizszN	NEXONplUSU6JRWK=
GT3TKB	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJwNUmxPVkh\|ryP	MlfvV2FPT0WU
SK-HEP-1	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTJwNUmyOlYh\|ryP	MXfTRW5ITVJ?
GAMG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJwNUmzPVQh\|ryP	MUDTRW5ITVJ?
SK-MES-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJwNkG4NFMh\|ryP	NITFWXBUSU6JRWK=
RO82-W-1	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFy1U2hKSzVyPUKuOlIxPTdizszN	NGjwfZhUSU6JRWK=
ECC10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrGNGxMUUN3ME2yMlcxOjB4IN88US=>	MVHTRW5ITVJ?
MCF7	M1fGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3FTWM2OD1{LkexOFY1KM7:TR?=	NGH6RlJUSU6JRWK=
D-283MED	M2\K[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTJwN{K0N{DPxE1?	NHvrPHJUSU6JRWK=
RPMI-7951	NX;mcm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWi3THhjUUN3ME2yMlc2Pjl2IN88US=>	M4DxN3NCVkeHUh?=
Ramos-2G6-4C10	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInZ[\|BKSzVyPUKuO\|cxQTlizszN	M2riZ3NCVkeHUh?=
KGN	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PVbmlEPTB;Mj64NVg5PCEQvF2=	MW\TRW5ITVJ?
NUGC-3	M4ewVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\zO4tKSzVyPUKuPFI2ODVizszN	MlfpV2FPT0WU
NCI-H292	NUDQUWRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2W2TGlEPTB;Mj64OVA2OyEQvF2=	NWryXVVSW0GQR1XS
Becker	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWmyWW1NUUN3ME2yMlk2QDN{IN88US=>	MoWyV2FPT0WU
NCI-H1299	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWf3Xo02UUN3ME2zMlA2OjZ\|IN88US=>	NGDLdXRUSU6JRWK=
ETK-1	NUPrSHVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjjeoNKSzVyPUOuNFU1OyEQvF2=	NF3EeodUSU6JRWK=
TK10	NXHnOXdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrTTWM2OD1\|LkKwNVY2KM7:TR?=	MX7TRW5ITVJ?
VMRC-RCZ	NUmydXI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfZTWM2OD1\|LkO2OFg5KM7:TR?=	MULTRW5ITVJ?
YH-13	MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPLR2ZXUUN3ME2zMlQ1ODd7IN88US=>	MmDxV2FPT0WU
DU-145	NXK1TnA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDXfWhKSzVyPUOuOFYzPjlizszN	M4Ti[nNCVkeHUh?=
SW1088	NHnTcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEH4NFlKSzVyPUOuOFc1PyEQvF2=	MYPTRW5ITVJ?
HOP-92	NXTLPFZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\I[mlEPTB;Mz61NFM1OiEQvF2=	NFS2XIdUSU6JRWK=
KP-N-YS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTNwNkKxN\|kh\|ryP	NEXHcoZUSU6JRWK=
NCI-H460	NWjtU3U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTNwNk[3N{DPxE1?	M{OzUnNCVkeHUh?=
U-2-OS	NEDUdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\BTWM2OD1\|LkeyOVM2KM7:TR?=	MXrTRW5ITVJ?
A101D	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTNwN{[5N\|Yh\|ryP	M{XCfnNCVkeHUh?=
MDA-MB-231	M4X0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37POGlEPTB;Mz64NVk2OSEQvF2=	MmLqV2FPT0WU
IST-MES1	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTNwOEOyJO69VQ>?	MUPTRW5ITVJ?
COR-L105	NHrDN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTRwMEG4JO69VQ>?	NIDMT3JUSU6JRWK=
NCI-H1437	NInJSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLVTWM2OD12LkCyN\|AzKM7:TR?=	NVLRc3IzW0GQR1XS
CAL-85-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTRwMEK0OlEh\|ryP	M121NnNCVkeHUh?=
MZ1-PC	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLrTWM2OD12LkG4OVU3KM7:TR?=	M4S2ZXNCVkeHUh?=
VM-CUB-1	NX3qV2VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLtTWM2OD12LkOxNlg1KM7:TR?=	M1fIUHNCVkeHUh?=
CHL-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n6[2lEPTB;ND6zNlE3QSEQvF2=	MoLKV2FPT0WU
MDA-MB-361	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorTTWM2OD12LkOzNVU{KM7:TR?=	MkLXV2FPT0WU
NCI-H661	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVntfGY5UUN3ME20MlUxODl{IN88US=>	MnLDV2FPT0WU
EW-11	NVr0TmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrJNFJPUUN3ME20MlUzOjNzIN88US=>	MkDjV2FPT0WU
BEN	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoS1TWM2OD12LkWyPFE2KM7:TR?=	NHe4[4hUSU6JRWK=
BFTC-909	NVLLblJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTRwNU[yO\|Uh\|ryP	NYrCS24zW0GQR1XS
NCI-H2087	M4Hr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojmTWM2OD12LkW4NVY1KM7:TR?=	NIe5eI5USU6JRWK=
RVH-421	NUC3foI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTRwNk[2PUDPxE1?	M4rUPXNCVkeHUh?=
P30-OHK	NYXmVnhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTRwNkiwNFgh\|ryP	M3;3WXNCVkeHUh?=
NCI-H28	NEHKbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHQOGtKSzVyPUSuPFE3PjFizszN	MnPCV2FPT0WU
ES6	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlexTWM2OD12LkizNFE3KM7:TR?=	MWfTRW5ITVJ?
769-P	Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTRwOEW5NlYh\|ryP	MYHTRW5ITVJ?
OE33	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTRwOEixOlEh\|ryP	NWPrNYtOW0GQR1XS
SW982	NX2xXWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2SxWWlEPTB;ND65OVA3OSEQvF2=	M1HuS3NCVkeHUh?=
A388	NHX5RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLwfW5KSzVyPUWuNFI6QDNizszN	MYXTRW5ITVJ?
TI-73	NHnLepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\CNpRSUUN3ME21MlA3OTl2IN88US=>	MV\TRW5ITVJ?
HCT-116	NVfYZnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo[5TWM2OD13LkC5PFg6KM7:TR?=	Mn\IV2FPT0WU
HuP-T3	M3fxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTDTWM2OD13LkG4O\|A6KM7:TR?=	NFHzbnBUSU6JRWK=
G-402	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLpTFRKSzVyPUWuNVk1OTZizszN	MlvIV2FPT0WU
NCI-H1792	NG[wd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;lRWlEPTB;NT6yOFYzOiEQvF2=	NFnSb4hUSU6JRWK=
NCI-H209	NVTEZVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnMT3BKSzVyPUWuNlU6PDJizszN	NI\o[IFUSU6JRWK=
NCI-H1650	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnoZYZKSzVyPUWuN\|A3OzRizszN	M1n5OnNCVkeHUh?=
LCLC-97TM1	M2XF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1S0bmlEPTB;NT6zNVgxQCEQvF2=	NXjGV4JjW0GQR1XS
S-117	NUL6[GFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrQUXpKSzVyPUWuN\|Y6PzZizszN	Mm\1V2FPT0WU
GI-ME-N	NEPLOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTOVYF[UUN3ME21MlM6PjhzIN88US=>	MY\TRW5ITVJ?
NCI-H2122	NXLNeoZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH[yNlJKSzVyPUWuOFk{QTdizszN	MYPTRW5ITVJ?
NCI-H1793	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjwUJJKSzVyPUWuOlc2QTNizszN	M1jpUnNCVkeHUh?=
C2BBe1	NU\1c\|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33pfWlEPTB;NT63NFA5QCEQvF2=	NXnwbppQW0GQR1XS
TE-12	NWHRV49mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTVwOEC1OVYh\|ryP	MmL5V2FPT0WU
LCLC-103H	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DZZWlEPTB;NT65NVch\|ryP	M{L0[3NCVkeHUh?=
A673	M2f5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTVwOUG5N\|Ih\|ryP	MorBV2FPT0WU
BB30-HNC	NVi4OY9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnToTWM2OD13Lkm4N\|Yh\|ryP	NXPMVGNYW0GQR1XS
SF295	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHwZ4JKSzVyPU[uNFA1OjJizszN	NGribWtUSU6JRWK=
KU-19-19	NF\qcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3yzXWlEPTB;Nj6wNVc{OSEQvF2=	M3qzeXNCVkeHUh?=
CFPAC-1	M3i3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrtTWM2OD14LkC0OFQ{KM7:TR?=	M1rObXNCVkeHUh?=
LoVo	NHLIe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzVTVB3UUN3ME22MlA2ODZ\|IN88US=>	NEjpPXNUSU6JRWK=
8505C	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULXcZFnUUN3ME22MlA4PTd\|IN88US=>	NV3M[WVmW0GQR1XS
GMS-10	NFfnUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\VTWM2OD14LkG1NFAzKM7:TR?=	MorvV2FPT0WU
Ca9-22	M1jhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTZwMU[3NUDPxE1?	M3;DS3NCVkeHUh?=
DOK	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTZwMkKwO\|Ih\|ryP	MoTKV2FPT0WU
FADU	NIXj[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTZwMk[wN\|kh\|ryP	NXy0bYpVW0GQR1XS
BxPC-3	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTZwMkezNkDPxE1?	NETl[YhUSU6JRWK=
CAL-33	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVH3TnlkUUN3ME22MlI6OjBzIN88US=>	M{HmO3NCVkeHUh?=
SHP-77	NVrBW2xzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTZwM{G1NVIh\|ryP	MX7TRW5ITVJ?
LXF-289	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUf2XFNKUUN3ME22MlM{PDV3IN88US=>	NYTuOIx3W0GQR1XS
GB-1	M330SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfkSGd{UUN3ME22MlM5OiEQvF2=	NF7JTHBUSU6JRWK=
KS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPjdWpKSzVyPU[uN\|g1PDdizszN	NXfvN4xkW0GQR1XS
D-502MG	NH7UflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTZwNEKzO\|Yh\|ryP	Mmr5V2FPT0WU
LAN-6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzycVd[UUN3ME22MlUyODJ\|IN88US=>	NETxeolUSU6JRWK=
H-EMC-SS	NIOyXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTZwNU[xOFch\|ryP	M4SwNnNCVkeHUh?=
LC-2-ad	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTtTWM2OD14Lk[wNFc3KM7:TR?=	MkLuV2FPT0WU
NCI-H1693	NIP5[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;wXFZSUUN3ME22MlYzOjF3IN88US=>	M{SxZ3NCVkeHUh?=
SK-N-FI	M1WyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3u2SmlEPTB;Nj63OVA1PCEQvF2=	MlPGV2FPT0WU
D-423MG	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC1RlhCUUN3ME22Mlc3OTF5IN88US=>	NVPEU25NW0GQR1XS
KNS-42	M4PlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTZwN{ixPVch\|ryP	NULINGhkW0GQR1XS
GCT	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TGcmlEPTB;Nj65N\|gh\|ryP	NYHxb25DW0GQR1XS
DSH1	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf1[ZJKSzVyPUeuNFY{OyEQvF2=	M3PkfXNCVkeHUh?=
D-247MG	M{mwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\GOoxKSzVyPUeuNFc5QDFizszN	M3\ybnNCVkeHUh?=
NCI-SNU-5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3jTWM2OD15LkG4N\|cyKM7:TR?=	MUfTRW5ITVJ?
TE-6	NIrIXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;0TWM2OD15LkKwOlAyKM7:TR?=	Mo\wV2FPT0WU
NOMO-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnMTWM2OD15LkKyNVI4KM7:TR?=	MkjGV2FPT0WU
NB17	NFv6OYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rNemlEPTB;Nz6zNFMxQSEQvF2=	MYHTRW5ITVJ?
EW-22	NEnoWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfzbox4UUN3ME23MlM1OzR6IN88US=>	NGXWNnpUSU6JRWK=
EW-13	MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvW[4t[UUN3ME23MlM2OTZ{IN88US=>	NGWzWY9USU6JRWK=
DOHH-2	NGryZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlW5TWM2OD15LkS0NFIh\|ryP	NVrY[o17W0GQR1XS
TGBC1TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\rblFKSzVyPUeuOFk5QTlizszN	NUjRZ41iW0GQR1XS
GR-ST	NV6ydWpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTdwNUK1PVQh\|ryP	NX\PeYhjW0GQR1XS
KYSE-520	NH;xSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\0eIRKSzVyPUeuOVU2OTVizszN	M1HMc3NCVkeHUh?=
CAPAN-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jWOWlEPTB;Nz61PVUyKM7:TR?=	MkLtV2FPT0WU
HCE-4	NHfBV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPTfJhUUUN3ME23MlYzOjd7IN88US=>	NV\h[4c4W0GQR1XS
MLMA	NXfUOJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\yTWM2OD15Lk[yPVU4KM7:TR?=	Ml\FV2FPT0WU
HT-144	NUnxbm9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rlSGlEPTB;Nz62OVM3QCEQvF2=	NVHNcllqW0GQR1XS
KYSE-180	NVyxcpFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\4U2lEPTB;Nz63NVE3QSEQvF2=	MXTTRW5ITVJ?
TE-5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGeybIVKSzVyPUeuPVU6PzFizszN	MVvTRW5ITVJ?
IGROV-1	NX2xU2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTdwOUi1OVEh\|ryP	NIn5dXRUSU6JRWK=
NCI-H1581	NEPuXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzUTWM2OD16LkCxNkDPxE1?	MkHlV2FPT0WU
SW1990	NHrrPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfRWJZKSzVyPUiuNFQ3PTlizszN	MlztV2FPT0WU
EFM-19	NHKxUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1G3R2lEPTB;OD6wPFU1PSEQvF2=	NXHFcnRnW0GQR1XS
OGR-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7YTm1KSzVyPUiuOFMxOjNizszN	NVjpbJhLW0GQR1XS
U-118-MG	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRThwNEO0OlMh\|ryP	MkjGV2FPT0WU
SK-OV-3	NEOzU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRThwNE[3OlUh\|ryP	MlvaV2FPT0WU
KNS-62	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXT1UFVCUUN3ME24MlUyPzZzIN88US=>	Ml;mV2FPT0WU
GOTO	NY\sN3NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\OemlEPTB;OD61O\|Y{PSEQvF2=	NYfBNow5W0GQR1XS
8305C	NVG1O5l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRThwN{C0PFQh\|ryP	NUXJc2t4W0GQR1XS
RPMI-2650	M{C0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRThwN{G5OVUh\|ryP	NW\QcVI1W0GQR1XS
NEC8	NGfy[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LHb2lEPTB;OD63OFMxPyEQvF2=	MlPDV2FPT0WU
KYSE-450	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRThwOE[1OFgh\|ryP	NGPjSG1USU6JRWK=
RMG-I	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofDTWM2OD17LkG0NFU5KM7:TR?=	MYPTRW5ITVJ?
CAKI-1	NXTsN\|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;j[WlEPTB;OT6zNVk4QSEQvF2=	M1;DVnNCVkeHUh?=
KYSE-510	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTlwM{W3O\|gh\|ryP	NU[0b45UW0GQR1XS
A4-Fuk	NXjGcIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7UNmtKSzVyPUmuN\|Y4ODFizszN	MnuxV2FPT0WU
AN3-CA	M1;lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TycmlEPTB;OT60OVQ1PCEQvF2=	MX;TRW5ITVJ?
SK-N-DZ	NWLB[4RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXre3JvUUN3ME25MlczQDR7IN88US=>	NHi3dWxUSU6JRWK=
HSC-2	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;JdXJZUUN3ME25Mlc3PjJ7IN88US=>	M3XmeXNCVkeHUh?=
EW-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTxW5ZOUUN3ME25Mlc6OzZ7IN88US=>	MW\TRW5ITVJ?
D-566MG	NWrXWZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTNWlN{UUN3ME25Mlg{PjZ2IN88US=>	NFrPT5ZUSU6JRWK=
COLO-792	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TjVGlEPTB;OT65PFc1PiEQvF2=	MXvTRW5ITVJ?
TE-10	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTFyLkCzPVYh\|ryP	M3\VbnNCVkeHUh?=
NCI-H650	M4[1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXETWM2OD1zMD60Nlg3KM7:TR?=	MnKzV2FPT0WU
U-266	M3z2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TZe2lEPTB;MUCuOFU2KM7:TR?=	MoX0V2FPT0WU
Detroit562	M2iwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2mz[WlEPTB;MUGuNFUyPSEQvF2=	NUTEVI1lW0GQR1XS
NH-12	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XvcmlEPTB;MUGuNVQ1PiEQvF2=	NHzUVpVUSU6JRWK=
CO-314	M4\4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvxTJlTUUN3ME2xNU4zQDR{IN88US=>	NV;w[Iw3W0GQR1XS
IST-MEL1	NUfvc\|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzoTWM2OD1zMT61N\|I{KM7:TR?=	MnnBV2FPT0WU
KNS-81-FD	M1vXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTFzLkW1Nlch\|ryP	MXfTRW5ITVJ?
SW1463	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDJfW9KSzVyPUGxMlU6QDlizszN	MV;TRW5ITVJ?
NCI-H23	NH:0SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL3PXJKSzVyPUGxMlY2PTJizszN	MVjTRW5ITVJ?
SK-MEL-2	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTFzLkexPVch\|ryP	M4rhW3NCVkeHUh?=
NB13	NEKwXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvOcW95UUN3ME2xNk4yPDl3IN88US=>	NH;lWYFUSU6JRWK=
Daoy	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELnXYJKSzVyPUGyMlI5PTZizszN	NW\ue45OW0GQR1XS
NCI-H1623	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnSbZdwUUN3ME2xNk4{QDBzIN88US=>	M3TDe3NCVkeHUh?=
NMC-G1	NGrnTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF[yPFZKSzVyPUGyMlcyPyEQvF2=	NX70PGZ7W0GQR1XS
DK-MG	NWXxUFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF{Lkm0PFIh\|ryP	M1\2cXNCVkeHUh?=
TCCSUP	NY\vTo1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fNbWlEPTB;MUOuNVI5PCEQvF2=	M4Lq[3NCVkeHUh?=
SCC-15	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTF\|LkK2OVEh\|ryP	MlzYV2FPT0WU
NOS-1	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoftTWM2OD1zMz6yPFk{KM7:TR?=	NHnhbZlUSU6JRWK=
RH-1	NXX6W5NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorETWM2OD1zMz6zNFM4KM7:TR?=	NFvIfGFUSU6JRWK=
SK-MEL-3	M1;p[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYmwSXd3UUN3ME2xN{4{PzJ6IN88US=>	NHvqSWNUSU6JRWK=
NB5	M4TzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoriTWM2OD1zMz60NFY4KM7:TR?=	M1LKZ3NCVkeHUh?=
SNU-387	NIrpOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF\|LkWwO\|Ih\|ryP	M33jTnNCVkeHUh?=
CAL-120	M{jQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHTb\|Y2UUN3ME2xN{43PzF6IN88US=>	NIXkfG5USU6JRWK=
Mo-T	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vTOWlEPTB;MUOuO\|A4KM7:TR?=	MXLTRW5ITVJ?
LNCaP-Clone-FGC	M2XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXVXIhKSzVyPUGzMlc6QTJizszN	M37ER3NCVkeHUh?=
CAN	NWjiWFM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDYW2Q4UUN3ME2xOE4xOjh6IN88US=>	MkP6V2FPT0WU
SK-MEL-30	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkKzTWM2OD1zND6wOlMh\|ryP	M{XL[XNCVkeHUh?=
COLO-678	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofzTWM2OD1zND6wPFIzKM7:TR?=	MV;TRW5ITVJ?
SCC-9	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnpRo1KSzVyPUG0MlExOjFizszN	NYLPXJhSW0GQR1XS
KINGS-1	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvUeIpwUUN3ME2xOE4yPDB{IN88US=>	MWHTRW5ITVJ?
SL-513	NHHOZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\S[WlEPTB;MUSuNVg4KM7:TR?=	MUXTRW5ITVJ?
HLE	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTF2LkO4OVIh\|ryP	MmDtV2FPT0WU
SW1573	Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkCzTWM2OD1zND60OFM2KM7:TR?=	Mnj1V2FPT0WU
KYSE-140	M{G1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LKVGlEPTB;MUSuOlMzPyEQvF2=	MlztV2FPT0WU
SK-PN-DW	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rS[WlEPTB;MUSuPFAxOSEQvF2=	MVnTRW5ITVJ?
A253	NYHINGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fWbGlEPTB;MUWuNFYzPSEQvF2=	NVzTTmo6W0GQR1XS
CAL-12T	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzGW2ZXUUN3ME2xOU41PjZ{IN88US=>	NFvHOZJUSU6JRWK=
COLO-679	M{OzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIi1UnBKSzVyPUG1Mlc3QDNizszN	M{XHeXNCVkeHUh?=
UACC-257	NYO0e3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF4LkGyNFEh\|ryP	MVvTRW5ITVJ?
U-87-MG	NEnMO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoX3TWM2OD1zNj6zOVI{KM7:TR?=	M2jLfXNCVkeHUh?=
HCC1806	NWHlNlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF4LkewO\|Eh\|ryP	M2LHN3NCVkeHUh?=
NCI-H2170	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTF5LkK0OFgh\|ryP	M3vEXnNCVkeHUh?=
AGS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PX[mlEPTB;MUeuN\|gxQCEQvF2=	MlfCV2FPT0WU
MEL-HO	M1z1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfFOWxKSzVyPUG3Mlc2ODNizszN	NWjKNHhwW0GQR1XS
SW48	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTF5Lke3NVYh\|ryP	NGfFVnBUSU6JRWK=
HuP-T4	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHruSGlKSzVyPUG4MlAzODZizszN	NYHsRoFsW0GQR1XS
NCI-H720	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHXN5VnUUN3ME2xPE4yPDB{IN88US=>	NXnEbJR5W0GQR1XS
RCC10RGB	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzJSmxKSzVyPUG4MlE3QTdizszN	MV3TRW5ITVJ?
HD-MY-Z	NHLrXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF6LkKyOVQh\|ryP	M3HsdHNCVkeHUh?=
A427	NHS0XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF6LkWwPVQh\|ryP	NGnkRpRUSU6JRWK=
HCC2998	NYXnOlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3n1WmlEPTB;MUiuOlA2OSEQvF2=	M{n2cHNCVkeHUh?=
EPLC-272H	NHfIWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPsTWM2OD1zOT6wOFM1KM7:TR?=	MmXPV2FPT0WU
C32	M3PVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnkfVdNUUN3ME2xPU4xPDVizszN	NHu0eVBUSU6JRWK=
UMC-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF7LkKxNlMh\|ryP	NID5UINUSU6JRWK=
CaR-1	M1jvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPDc25KSzVyPUG5MlY5ODRizszN	M{LCfHNCVkeHUh?=
KYSE-410	NGHSeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV2yT5NuUUN3ME2xPU46OTN7IN88US=>	MnH6V2FPT0WU
HuCCT1	NXHsNXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmOzTWM2OD1{MD62Nlk1KM7:TR?=	Mon4V2FPT0WU
LB996-RCC	M1TFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fEVGlEPTB;MkCuO\|E3QCEQvF2=	NWKzd2JIW0GQR1XS
KYSE-70	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PndmlEPTB;MkCuPFA2QSEQvF2=	NYHtfZROW0GQR1XS
CAL-72	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHUUHVKSzVyPUKwMlkyPSEQvF2=	NWDlTGdqW0GQR1XS
Capan-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\qTWM2OD1{MT6wOFE{KM7:TR?=	MWDTRW5ITVJ?
PANC-08-13	NXvI[FhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnUeVlrUUN3ME2yNU4zPTF3IN88US=>	NYi3PYhzW0GQR1XS
SBC-1	M4HYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfwc3hUUUN3ME2yNU4{ODhzIN88US=>	NYPzcnlWW0GQR1XS
MFM-223	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJzLkOzOFIh\|ryP	MVPTRW5ITVJ?
BB49-HNC	M2mzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJzLkW3NVYh\|ryP	MmS3V2FPT0WU
SH-4	NYG4b20xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;pVWlEPTB;MkGuOlYyQCEQvF2=	NFLIbY9USU6JRWK=
HuO9	M3\tSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTJzLkm4NlUh\|ryP	MYLTRW5ITVJ?
AM-38	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfNUXdpUUN3ME2yNk4xPDh3IN88US=>	NGLVdI1USU6JRWK=
A431	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPyVIxKSzVyPUKzMlIyOTlizszN	NVzxVJBCW0GQR1XS
YAPC	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjleYFKSzVyPUKzMlI3PTFizszN	M1GwcnNCVkeHUh?=
LU-139	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTZTWM2OD1{Mz60PFA6KM7:TR?=	M1jNXHNCVkeHUh?=
HEC-1	M3Psbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3i3O2lEPTB;MkOuOFk{PyEQvF2=	MWHTRW5ITVJ?
SCC-25	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrNWoZKSzVyPUK0MlMxODZizszN	M3fx[XNCVkeHUh?=
HT-29	M33zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXT6Xm9bUUN3ME2yOE4{QDJ\|IN88US=>	MWXTRW5ITVJ?
PC-14	NWnhSmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJ2Lk[1O\|Eh\|ryP	MWfTRW5ITVJ?
Calu-6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJ3LkWwO\|Eh\|ryP	NU\uNmRPW0GQR1XS
SJRH30	NXPDS\|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTJ3Lk[0PVYh\|ryP	NEXMd41USU6JRWK=
ChaGo-K-1	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjObHhKSzVyPUK2MlE3OjlizszN	MXLTRW5ITVJ?
IA-LM	NVGxSml1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJ4LkO2OFUh\|ryP	Ml\rV2FPT0WU
GP5d	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnqXmR7UUN3ME2yOk41PDlzIN88US=>	NInQco1USU6JRWK=
NCI-H2291	NHzDTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkezTWM2OD1{Nj62OVQyKM7:TR?=	MXLTRW5ITVJ?
BALL-1	NUi1W4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[1eY9KSzVyPUK2Mlk{QTdizszN	M1;mSXNCVkeHUh?=
HCC1954	NVTVZ45XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJ4Lkm4NFgh\|ryP	NUGzXIdiW0GQR1XS
NCI-H2452	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zM[mlEPTB;MkeuOFE3OyEQvF2=	MYfTRW5ITVJ?
LU-99A	NHnTTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJ5LkW1PFIh\|ryP	M2PJWXNCVkeHUh?=
NTERA-S-cl-D1	NF64[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[5dW9QUUN3ME2yO{44Ojl7IN88US=>	M1m0XnNCVkeHUh?=
PANC-10-05	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrqRlVKSzVyPUK3Mlc4PzVizszN	NHP5[3hUSU6JRWK=
NCI-H2405	NXPHcXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPSTWM2OD1{Nz65N\|g4KM7:TR?=	MlzLV2FPT0WU
MDA-MB-415	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DkNmlEPTB;MkiuOFE{PyEQvF2=	NI\TXYFUSU6JRWK=
NCI-H2342	M2PPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXj1ZWFiUUN3ME2yPE42OjhzIN88US=>	MWTTRW5ITVJ?
TGBC24TKB	M3ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XiVmlEPTB;MkiuO\|EyPyEQvF2=	NVzBV\|FkW0GQR1XS
LU-134-A	NHv5b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvlUGlHUUN3ME2yPE46OjZzIN88US=>	NI\GfoFUSU6JRWK=
SCC-4	NILmSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNzLkC0PVQh\|ryP	MV\TRW5ITVJ?
Saos-2	NIn6ZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fReGlEPTB;M{GuPVMxPiEQvF2=	NVHMSldJW0GQR1XS
RERF-LC-MS	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTN{LkiyN\|Eh\|ryP	M{HXUnNCVkeHUh?=
M14	M3HYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIK1PWlKSzVyPUOyMlk4PjRizszN	M{nmN3NCVkeHUh?=
HPAF-II	NXXEdFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;3RWlEPTB;M{OuOVAyOSEQvF2=	MWPTRW5ITVJ?
NCI-H1755	M2[2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkmzTWM2OD1\|ND6zN\|A2KM7:TR?=	MmrYV2FPT0WU
D-392MG	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLoTWM2OD1\|NT64Olc1KM7:TR?=	MVPTRW5ITVJ?
A704	Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LIcGlEPTB;M{[uNFQzPyEQvF2=	MlXuV2FPT0WU
CP50-MEL-B	M3zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTN4LkG5NVEh\|ryP	MnjJV2FPT0WU
EW-18	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrx[\|lKSzVyPUO2MlQ2OiEQvF2=	NX7JeIJpW0GQR1XS
WM-115	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDQTWM2OD1\|Nj64NFk6KM7:TR?=	MVjTRW5ITVJ?
LU-65	NUXYdnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPiTWM2OD1\|Nz6xOFE4KM7:TR?=	NYTEO3VqW0GQR1XS
NCI-H1563	NFfZflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT1TWM2OD1\|Nz6yOFg1KM7:TR?=	NHzlO5BUSU6JRWK=
DBTRG-05MG	M3HIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDNTWM2OD1\|OD6wOlkyKM7:TR?=	MnvsV2FPT0WU
NCI-H630	NXrOW\|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\VO25KSzVyPUO4MlQ4OTRizszN	NWTkcIVRW0GQR1XS
NCI-H1155	NGrPfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rSZWlEPTB;M{muNlQzKM7:TR?=	M1jFRXNCVkeHUh?=
OVACR-3	NEj1OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXuc5BbUUN3ME2zPU46OTl3IN88US=>	MU\TRW5ITVJ?
OAW-42	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF62[3dKSzVyPUSwMlQzPThizszN	Mm\qV2FPT0WU
JVM-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXoTWM2OD12MT6yOFE2KM7:TR?=	NXHiOHZ5W0GQR1XS
C3A	NICzZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rRNGlEPTB;NEGuN\|Q1PyEQvF2=	M4nOTnNCVkeHUh?=
HT55	NHWwXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfVZVdKSzVyPUSyMlI5PDFizszN	NXr2WIlWW0GQR1XS
OVCAR-4	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLmTWM2OD12Mj6yPVc1KM7:TR?=	M2T3RXNCVkeHUh?=
MEG-01	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXWNXVKSzVyPUSyMlQ3OTZizszN	NFjpb\|FUSU6JRWK=
NCI-H82	NH3EOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTR\|Lkm4PVIh\|ryP	M4\VcnNCVkeHUh?=
JEG-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfmTWM2OD12ND65OFch\|ryP	M2C2U3NCVkeHUh?=
BPH-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTR4LkO5PVgh\|ryP	M3fPSXNCVkeHUh?=
MPP-89	MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLYS3B6UUN3ME20O{4zQDl6IN88US=>	NVvTZYwzW0GQR1XS
ALL-PO	NF7mWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfwTWM2OD12Nz60NVg5KM7:TR?=	M{nDUXNCVkeHUh?=
HT	NHrmTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\tcGlEPTB;NEeuOFkzKM7:TR?=	M4\zO3NCVkeHUh?=
NCI-H2347	M1[zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHVTWM2OD12OD6wO\|E2KM7:TR?=	MnTmV2FPT0WU
A2780	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nhZWlEPTB;NEmuOFIzQCEQvF2=	M1HqfXNCVkeHUh?=
KARPAS-299	M2PBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX61TG9EUUN3ME20PU42OTF7IN88US=>	MoX2V2FPT0WU
NCI-H1651	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTR7Lki4NlEh\|ryP	MWfTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

体内試験

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験： ^[1]	- 合併細胞株： Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 濃度： 0.01-1 μM 反応時間： 24 hours 実験の流れ： Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. 製剤： Dissolved in sodium lactate buffer (50 mM, pH 4.0) 投薬量： 0-150 mg/kg 投与方法： Given by gavage (参考用のみ)

参考

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- 合併

溶解度 (25°C)

体外	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): Saline 混合させたのち直ちに使用することを推奨します。	6 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Palbociclib (PD-0332991) HCl SDFをダウンロードする

分子量	483.99
化学式	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
保管	3年-20°C粉
保管	2 years-80°C in solvent
別名	N/A
Smiles	Cl.CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2N(C5CCCC5)C1=O

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03870919	Not yet recruiting	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 15 2019	Not Applicable
NCT03900884	Not yet recruiting	Drug: Venetoclax\|Drug: Palbociclib\|Drug: Letrozole	Breast Neoplasm Female	Peter MacCallum Cancer Centre Australia	September 2019	Phase 1
NCT03844997	Recruiting	Drug: Palcociclib\|Drug: CPX-351	Acute Myeloid Leukemia\|AML	Aziz Nazha\|Case Comprehensive Cancer Center	May 31 2019	Phase 1\|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

相関CDK製品

SU9516

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Purvalanol A

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

研究分野別

製品類型

Palbociclib (PD-0332991) HCl

文献中Selleckの製品使用例(155)

製品安全説明書

CDK阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Palbociclib (PD-0332991) HCl SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技術サポート

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

相関CDK製品